Number of systematic reviews (SRs) | 210 |
 Meta-analysis | 165 |
 Narrative analysis only | 45 |
Studies included in SRs | 210 |
 RCTs only | 193 |
 NRSIs only | 1 |
 Both RCTs and NRSIs | 16 |
RCTs per SR: Median (range) | 9 (1–77) |
NRSIs per SR: Median (range) | 4 (1–18) |
Participants per SR: Median (range) | 750 (42–9263) |
Publication year | |
 2010–2012 | 20 |
 2013–2014 | 33 |
 2015–2016 | 37 |
 2017–2018 | 54 |
 2019–2020 | 66 |
Publication language | |
 English | 155 |
 Chinese | 54 |
 Korean | 1 |
Country / region of first author | |
 China, Hong Kong, Taiwan | 139 |
 United States of America, Canada, Brazil | 35 |
 Western Europe | 19 |
 South Korea, Singapore, Thailand | 10 |
 Australia, New Zealand | 6 |
Funding | |
 Government / national grants | 84 |
 University | 15 |
 Charity | 3 |
 No information | 108 |
Disease / condition | |
 Healthy adolescents/ adults | 8 |
 Multiple chronic diseases | 9 |
 Falls, balance, other falls risk factors | 32 |
 Hypertension | 15 |
 Cancer (breast cancer n = 8) | 15 |
 Diabetes mellitus | 14 |
 Cognitive impairment | 13 |
 Parkinson’s disease | 13 |
 Chronic obstructive pulmonary disease | 13 |
 Cerebrovascular disease (stroke) | 11 |
 Mental health | 11 |
 Ischaemic heart disease | 10 |
 Osteoarthritis (knee n = 5) | 10 |
 Osteoporosis / osteopenia | 8 |
 Heart failure | 6 |
 Sleep disorders / quality | 6 |
 3 SRs each for: Low back pain, chronic pain | |
 2 SRs each for: Multiple sclerosis, rheumatoid arthritis | |
 1 SR each for: Hyperlipidaemia, fatigue, fibromyalgia, frailty, immunity/HIV infection, adverse effects |